WAVE LIFE SCIENCES LTD (WVE)
Health Care · NASDAQ
A clinical-stage RNA medicines company using its proprietary PRISM platform to develop potential treatments for obesity, rare genetic disorders, and metabolic diseases.
What WAVE LIFE SCIENCES LTD does
Wave Life Sciences is a clinical-stage biotechnology company developing RNA medicines (oligonucleotides) to treat rare and common disorders. The company's proprietary PRISM platform combines multiple RNA-targeting modalities—including RNA interference (RNAi/SpiNA), RNA editing (AIMers), antisense silencing, and splicing—with novel chemistry modifications to optimize pharmacological properties and avoid complex delivery vehicles. Its lead programs target obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006), PNPLA3 I148M liver disease (WVE-008), Duchenne muscular dystrophy, and Huntington's disease, with additional preclinical programs in development.
Themes: ["RNA medicines / oligonucleotides"]
Fundamentals
- Price$6.31 as of 2026-07-09 close
- Market cap$1.3B as of 2026-07-10
- 1-year return-18.1% as of 2026-07-09 close
- Net margin-255.7% as of 2026-07-10
- ROE-55.7% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-31.6% as of 2026-07-10
- Revenue CAGR (3y)+127.1% SEC XBRL
- Beta-1.33 as of 2026-07-10
Key risks (from latest filing)
["Clinical development risk: the company's ability to advance multiple clinical programs depends on preclinical and clinical trial success, which may not support further development; regulatory approval timelines are uncertain and subject to regulatory agency actions affecting initiation, timing, and progress of trials."]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.